CELLDEX THERAPEUTICS,INC. (NASDAQ:CLDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k

7 years ago

CELLDEX THERAPEUTICS,INC. (NASDAQ:CLDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02(e).Compensatory Arrangements of Certain Officers.

Celldex Therapeutics,Inc. (the “Company”) entered into amended and restated employment agreements with each of its executive officers: Anthony S. Marucci, President and Chief Executive Officer; Sam Martin, Senior Vice President, Chief Financial Officer and Secretary; Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer, Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer, Sarah Cavanaugh, Senior Vice President of Corporate Affairs and Administration; Margo Heath-Chiozzi, M.D., Senior Vice President of Regulatory Affairs; Elizabeth Crowley, Senior Vice President and Chief Product Development Officer; and Richard Wright, Ph.D., Senior Vice President and Chief Commercial Officer. Each of these employment agreements is effective January1, 2018.

The executive employment agreements between the Company and its executive officers were amended to reflect current applicable law, standardize language in the contracts and conform to the Company’s current policies.

The employment agreements have an initial term through December31, 2018 and shall automatically renew for additional one year terms unless either party gives ninety (90) days prior written notice of its intent not to renew. The Company may terminate the employment agreements without cause, on 90-days’ prior notice, or for cause, subject to a 30-day cure period in certain circumstances. The executive may terminate the employment agreement for good reason (as defined in the executive employment agreement) on 30-days’ prior notice.

The foregoing description of the employment agreements with each of the Company’s executive officers is intended to be a summary and is qualified in its entirety by reference to such documents, which are attached as Exhibits 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7 and 10.8 and which are incorporated by reference herein.

Item 9.01Financial Statements and Exhibits.

(d)	ExhibitNo.	Description.
10.1	Amended and Restated Employment Agreement, dated as of January1, 2018, by and between Celldex Therapeutics,Inc. and Anthony S. Marucci
10.2	Amended and Restated Employment Agreement, dated as of January1, 2018, by and between Celldex Therapeutics,Inc. and Sam Martin
10.3	Amended and Restated Employment Agreement, dated as of January1, 2018, by and between Celldex Therapeutics,Inc. and Tibor Keler, Ph.D.
10.4	Amended and Restated Employment Agreement, dated as of January1, 2018, by and between Celldex Therapeutics,Inc. and Ronald Pepin, Ph.D.
10.5	Amended and Restated Employment Agreement, dated as of January1, 2018, by and between Celldex Therapeutics,Inc. and Sarah Cavanaugh
10.6	Amended and Restated Employment Agreement, dated as of January1, 2018, by and between Celldex Therapeutics,Inc. and Margo Heath-Chiozzi, M.D.

Celldex Therapeutics, Inc. ExhibitEX-10.1 2 a17-28883_1ex10d1.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the Agreement) is entered into on January 1,…To view the full exhibit click here
About CELLDEX THERAPEUTICS,INC. (NASDAQ:CLDX)
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.